259 related articles for article (PubMed ID: 36229831)
1. Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review.
Bozinoff N; Tardelli VS; Rubin-Kahana DS; Le Foll B
Harm Reduct J; 2022 Oct; 19(1):113. PubMed ID: 36229831
[TBL] [Abstract][Full Text] [Related]
2. High Interest in Injectable Opioid Agonist Treatment With Hydromorphone Among Urban Syringe Service Program Participants.
Fox AD; Riback L; Perez-Correa A; Ohlendorf E; Ghiroli M; Behrends CN; López-Castro T
Subst Use Addctn J; 2024 Jan; 45(1):44-53. PubMed ID: 38258851
[TBL] [Abstract][Full Text] [Related]
3. Hospital Initiated Injectable Opioid Agonist Therapy for the Treatment of Severe Opioid Use Disorder: A Case Series.
Brar R; Fairbairn N; Colizza K; Ryan A; Nolan S
J Addict Med; 2021 Apr; 15(2):163-166. PubMed ID: 32769776
[TBL] [Abstract][Full Text] [Related]
4. Treatment History and Interest in Injectable Opioid Agonist Treatment With Hydromorphone Among People Who Inject Drugs.
Ohlendorf E; Perez-Correa A; Riback L; Ghiroli M; Lopez-Castro T; Fox AD
J Addict Med; 2023 May-Jun 01; 17(3):e148-e155. PubMed ID: 37267166
[TBL] [Abstract][Full Text] [Related]
5. Measuring the preferences of injectable opioid agonist treatment (iOAT) clients: Development of a person-centered scale (best-worst scaling).
Dobischok S; Metcalfe R; Matzinger E; Palis H; Marchand K; Harrison S; MacDonald S; Byres D; Schechter M; Bansback N; Oviedo-Joekes E
Int J Drug Policy; 2023 Feb; 112():103948. PubMed ID: 36586152
[TBL] [Abstract][Full Text] [Related]
6. Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study.
Oviedo-Joekes E; MacDonald S; Boissonneault C; Harper K
Subst Abuse Treat Prev Policy; 2021 Mar; 16(1):22. PubMed ID: 33673847
[TBL] [Abstract][Full Text] [Related]
7. The FASTER-BUP Study, Extended-Release Injectable Buprenorphine for the Treatment of Opioid Use Disorder Among Individuals at High Risk of Overdose: Protocol for an Observational Prospective Study.
Langlois J; Nolan S; Dickhout P; Cui Z; Paterson J; Fairbairn N; Socías ME
Subst Use Addctn J; 2024 Apr; 45(2):176-180. PubMed ID: 38254287
[TBL] [Abstract][Full Text] [Related]
8. Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross-sectional study in three Australian cities.
Nielsen S; Sanfilippo P; Belackova V; Day C; Silins E; Lintzeris N; Bruno R; Grebely J; Lancaster K; Ali R; Bell J; Dietze P; Degenhardt L; Farrell M; Larance B
Addiction; 2021 Jun; 116(6):1482-1494. PubMed ID: 33067836
[TBL] [Abstract][Full Text] [Related]
9. Injectable opioid agonist treatment: An evolutionary concept analysis.
Haines M; O'Byrne P
Res Nurs Health; 2021 Aug; 44(4):664-671. PubMed ID: 33993526
[TBL] [Abstract][Full Text] [Related]
10. Opioid-induced analgesia among persons with opioid use disorder receiving methadone or buprenorphine: A systematic review of experimental pain studies.
De Aquino JP; Parida S; Avila-Quintero VJ; Flores J; Compton P; Hickey T; Gómez O; Sofuoglu M
Drug Alcohol Depend; 2021 Nov; 228():109097. PubMed ID: 34601272
[TBL] [Abstract][Full Text] [Related]
11. Supervised injectable opioid agonist therapy in a supported housing setting for the treatment of severe opioid use disorder.
Brar R; Sutherland C; Nolan S
BMJ Case Rep; 2019 Aug; 12(7):. PubMed ID: 31371332
[TBL] [Abstract][Full Text] [Related]
12. Medications for management of opioid use disorder.
Koehl JL; Zimmerman DE; Bridgeman PJ
Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids.
Barocas JA; Morgan JR; Fiellin DA; Schackman BR; Eftekhari Yazdi G; Stein MD; Freedberg KA; Linas BP
Int J Drug Policy; 2019 Oct; 72():160-168. PubMed ID: 31085063
[TBL] [Abstract][Full Text] [Related]
14. Perinatal Injectable Opioid Agonist Therapy (iOAT) Administration: A Case Series.
Patricelli CJ; Chai J; Gordon S; Gouin IJ; Carter N; Stewart K; Paquette V; Urbanoski K; Albert A
J Addict Med; 2023 Jul-Aug 01; 17(4):431-438. PubMed ID: 37579103
[TBL] [Abstract][Full Text] [Related]
15. Modeling the cost and impact of injectable opioid agonist therapy on overdose and overdose deaths.
Tse WC; Scott N; Dietze P; Nielsen S
J Subst Abuse Treat; 2022 Dec; 143():108871. PubMed ID: 36182753
[TBL] [Abstract][Full Text] [Related]
16. Willingness to receive intravenous buprenorphine treatment in opioid-dependent people refractory to oral opioid maintenance treatment: results from a community-based survey in France.
Roux P; Rojas Castro D; Ndiaye K; Briand Madrid L; Laporte V; Mora M; Maradan G; Morel S; Spire B; Carrieri P
Subst Abuse Treat Prev Policy; 2017 Nov; 12(1):46. PubMed ID: 29096661
[TBL] [Abstract][Full Text] [Related]
17. Mobile, Community-Based Buprenorphine Treatment for Veterans Experiencing Homelessness With Opioid Use Disorder: A Pilot, Feasibility Study.
Iheanacho T; Payne K; Tsai J
Am J Addict; 2020 Nov; 29(6):485-491. PubMed ID: 32367557
[TBL] [Abstract][Full Text] [Related]
18. Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans.
Eydt E; Glegg S; Sutherland C; Meador K; Trew M; Perreault M; Goyer MÈ; Le Foll B; Turnbull J; Fairbairn N
CMAJ Open; 2021; 9(1):E115-E124. PubMed ID: 33622764
[TBL] [Abstract][Full Text] [Related]
19. Can Treatment for Substance Use Disorder Prescribe the same Substance as that Used? The Case of Injectable Opioid Agonist Treatment.
Steel D; Tekin Ş
Kennedy Inst Ethics J; 2021; 31(3):271-301. PubMed ID: 34565745
[TBL] [Abstract][Full Text] [Related]
20. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
